


Transforming Biotech @ Bayer

Industrialization of Cell Therapies through Shared Manufacturing Platforms to bring Health for All

Jens H. Vogel, PhD SVP & Global Head, Bayer Biotech Pharmaceuticals Product Supply


November 2023





Bayer's Global Biotech Network Covers the Entire BT Continuum

End-to-End Large Molecule Development & Supply, as well as CGT Industrialization



Biotech HQ Site



Making it Real Requires Close Partnership Between Innovation & Industrialization Engines

PS BT Continuum to Provide Shared CMC Service for CGT Industrialization

Research + Early Dev

Development & Early Phase Clinic Supply

Pivotal Clinical Supply & Launch

Market Supply

Bayer Platform Companies & Partners Early Phase, *Research Driven* Companies & Assets

BLA Enabling CMC Development & Mfg for S*mooth Commercialization* Leverage PS BT Strengths, Synergies & Flexible Modular Platforms

IND Enabling CMC Dev



Other Partners...

Other Partners...

Arm's Length Innovation Engines

PS Biotech Industrialization Engine




Berkeley Late Stage / Launch





How Do You Industrialize Complex Biopharmaceutical Products?

Some Lessons Learned from Industrialization of Large Molecules



Industry Convergence on "Consensus Manufacturing Platform"

- Fed-batch bioreactors (2,000-20,000L) followed by Protein A based purification scheme
- CHO as standard workhorse; Culture Media & Feed-strategy





30th October 2009

Number of antibody therapeutics granted a first approval in either the US or EU each year, 15 Cancer Year of first US or EU approval

https://www.antibodysociety.org/resources/approved-antibodies/


Quality-by-design based CMC approach

- Fundamental Product understanding
 - What are the CQAs determining Safety & Efficacy?
- In-depth Process understanding
 - What are the CPPs?
 - What are the KPPs?
- Control strategy



Biotech Clusters

- Critical mass of talent & expertise crucial in early phase of technology development
- Maturing of technology platforms enables "commoditizing"





Bayer Biotech's CT Platform Vision to Enable Industrialization of Cell Therapies


A Comprehensive Global CT Industrialization Program Containing 5 Elements

"Software" = CT Process Platform

"Hardware" = CT EQT Platform "Operating System" = CMC Ecosystem

People & Culture

Flexible Facilities













Target

- Fundamental understanding of cells as products and their biology
- In-depth process understanding
- Culture media platform
- Small-scale models
- Scale-up strategies

- Well- characterized, automated, robust EQT **modules tailored** to process needs
- Engineering and automation specifications
- Plug and play systems


- Development Plan & CMC
 Strategy for CT products
- QbD based workflows supported by efficient, datadriven decision making
- Control strategy
- Phase-appropriate filing templates
- Building diverse highperformance team, strong CT competencies and capabilities
- Collaborative, "No Silo" culture
- Driven by one common goal
- Strong internal and external partner network

- Flexible facilities to enable efficient late-stage development & launch
- Modular, flexible & rapid deployment of "capacity on demand"



Our Vision: A Modular, Flexible Hardware Platform Covering Diverse Allogeneic Cell Therapies

How to Build an End-to-End "Consensus Platform" Able to Industrialize Diverse Assets





We can only do it together!

Expanding partnerships with academic and industrial leaders for industrialization platforms



Thank You!

